Dianthus Therapeutics DNTH Royalty — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
There is a sales or usage-based royalty exception within ASC 606 that applies when a license of intellectual property is the predominant item to which the royalty relates. In accordance with this royalty exception, the Company will recognize royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company has not recorded any royalty revenue to date.
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's royalty — revenue?
- Dianthus Therapeutics (DNTH) reported royalty — revenue of $0 in Q1 2026.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty-based arrangements associated with specific intellectual property or licensed technology, excluding any taxes collected from customers. It serves as a key indicator of the commercial viability and market adoption of the company's proprietary assets. For a clinical-stage biotechnology firm, this tracks the inflow of funds derived from licensing agreements or commercialized partnerships.
Ask your AI about Dianthus Therapeutics's royalty — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
